We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




ABO Blood Group Related to Specific Immune Response to Anti-SARS-CoV-2

By LabMedica International staff writers
Posted on 31 Jan 2022
Print article
Image: The MACSQuant Analyzer 16 is engineered to expand the horizons of automated data acquisition with 16 optical parameters (Photo courtesy of Miltenyi Biotec)
Image: The MACSQuant Analyzer 16 is engineered to expand the horizons of automated data acquisition with 16 optical parameters (Photo courtesy of Miltenyi Biotec)
Markers of the protective humoral response, such as total anti-SARS-CoV-2 immunoglobulins and neutralizing antibodies, have been observed to decrease in convalescent individuals, even though a potential long-lasting humoral B-cell memory subset was detected.

The detection of these specific T-cells comprises evidence for potential preexisting immunity mediated by T-cells cross-reactive to human common-cold coronaviruses, which might protect against SARS-CoV-2 infection. Induced T-cell immunity also appears to play a critical role in SARS-CoV-2 clearance, with studies reporting strong T-cell responses in acute infection up to the convalescence phase.

Immunologists at the Gregorio Marañón University General Hospital (Madrid Spain) collected blood samples 12 to 305 days after positive polymerase chain reactions (PCRs) from 35 recovered individuals infected by SARS-CoV-2. Peripheral blood mononuclear cells were stimulated with SARS-CoV-2-derived peptide pools, such as the spike (S), nucleocapsid (N) and membrane (M) proteins, and the team quantified anti-S immunoglobulins in plasma.

Whole blood was labeled for surface markers to determine the absolute numbers of lymphocytes or CD4+ and CD8+ T cells. Absolute numbers of cellular subsets were determined using Flow-Count Fluorospheres (Beckman Coulter, Nyon, Switzerland). Flow cytometry analyzed surface markers using a MACSQuant Analyzer 16 cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany). Peptide-specific T-cells were characterized after six hours of stimulation by cell surface and intracellular cytokine staining and the cells were then analyzed by flow cytometry, using a Beckman Coulter Gallios cytometer. To detect the presence or absence of A, B, and/or RhD antigens on red blood cells, DiaClon Anti-A, DiaClon Anti-B, DiaClon Anti-AB, and DiaClon Anti-D (Bio-Rad, Basel, Switzerland) were used.

The investigators reported that after 10 months post-infection, they observed a sustained SARS-CoV-2-specific CD4+ T-cell response directed against M-protein, but responses against S- or N-proteins were lost over time. They also demonstrated that O-group individuals presented significantly lower frequencies of specific CD4+ T-cell responses against membrane glycoprotein (Pep-M) than non O-group individuals. The non O-group subjects also needed longer to clear the virus, and they lost cellular immune responses over time, compared to the O-group individuals, who showed a persistent specific immune response against SARS-CoV-2.

The authors concluded that their results confirmed the existence of SARS-CoV-2-specific CD4+ T-cell and humoral responses in the majority of the individuals who had recovered from COVID-19 at 10 months post-infection. However, the response generated by the virus was identified as a predominantly CD4+ T-cell over CD8+ T-cell response, with more robust responses against M- or S-peptide pools over nucleocapsid phosphoprotein (Pep-N). A more in-depth analysis demonstrated that the intensity of the humoral and memory T-cell response might be related to the ABO blood group and age. The study was published in the January 2022 issue of the journal Virulence.

Related Links:
Gregorio Marañón University General Hospital
Beckman Coulter
Miltenyi Biotec
Bio-Rad


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.